Compare Dishman Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs NOVARTIS - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA NOVARTIS DISHMAN PHARMA/
NOVARTIS
 
P/E (TTM) x 25.1 2,089.8 1.2% View Chart
P/BV x 3.3 27.7 12.1% View Chart
Dividend Yield % 0.7 1.6 41.7%  

Financials

 DISHMAN PHARMA   NOVARTIS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
NOVARTIS
Mar-19
DISHMAN PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs374980 38.2%   
Low Rs129600 21.5%   
Sales per share (Unadj.) Rs197.8198.7 99.5%  
Earnings per share (Unadj.) Rs21.221.0 101.1%  
Cash flow per share (Unadj.) Rs34.722.3 156.0%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.81.3 62.8%  
Book value per share (Unadj.) Rs179.9307.5 58.5%  
Shares outstanding (eoy) m80.6924.69 326.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.0 32.0%   
Avg P/E ratio x11.937.7 31.5%  
P/CF ratio (eoy) x7.235.5 20.4%  
Price / Book Value ratio x1.42.6 54.4%  
Dividend payout %9.447.7 19.8%   
Avg Mkt Cap Rs m20,30619,508 104.1%   
No. of employees `0000.80.6 142.7%   
Total wages/salary Rs m5,3551,171 457.3%   
Avg. sales/employee Rs Th19,252.78,445.4 228.0%   
Avg. wages/employee Rs Th6,459.52,015.7 320.5%   
Avg. net profit/employee Rs Th2,064.1891.0 231.6%   
INCOME DATA
Net Sales Rs m15,9614,907 325.3%  
Other income Rs m265783 33.9%   
Total revenues Rs m16,2265,689 285.2%   
Gross profit Rs m4,103123 3,341.4%  
Depreciation Rs m1,09132 3,429.6%   
Interest Rs m94416 5,939.6%   
Profit before tax Rs m2,334858 272.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624340 183.4%   
Profit after tax Rs m1,711518 330.5%  
Gross profit margin %25.72.5 1,027.3%  
Effective tax rate %26.739.6 67.4%   
Net profit margin %10.710.6 101.6%  
BALANCE SHEET DATA
Current assets Rs m11,0188,055 136.8%   
Current liabilities Rs m9,5171,850 514.4%   
Net working cap to sales %9.4126.4 7.4%  
Current ratio x1.24.4 26.6%  
Inventory Days Days11045 245.5%  
Debtors Days Days3534 102.7%  
Net fixed assets Rs m16,304150 10,883.9%   
Share capital Rs m161123 130.8%   
"Free" reserves Rs m12,9077,469 172.8%   
Net worth Rs m14,5167,592 191.2%   
Long term debt Rs m4,1890-   
Total assets Rs m29,8059,824 303.4%  
Interest coverage x3.554.9 6.3%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.50.5 107.2%   
Return on assets %8.95.4 164.0%  
Return on equity %11.86.8 172.9%  
Return on capital %17.511.5 152.3%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95258 8,596.4%   
Fx outflow Rs m6971,326 52.5%   
Net fx Rs m4,255-1,269 -335.4%   
CASH FLOW
From Operations Rs m2,786-1,943 -143.4%  
From Investments Rs m-1,5292,742 -55.8%  
From Financial Activity Rs m-941-298 315.6%  
Net Cashflow Rs m316501 63.1%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 2.0 185.0%  
FIIs % 12.7 1.6 793.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 21.5 102.8%  
Shareholders   46,261 41,647 111.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   FDC  FULFORD INDIA  PROCTER & GAMBLE HEALTH  STERLING BIOTECH  TORRENT PHARMA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Trades 279 Points Lower; Indicates Gap-Down Opening for Indian Stock Markets(SGX Nifty)

The SGX Nifty opened on a negative note today. At 8:10 am, it was trading down by 279 points, or 1.9% lower at 14,900 levels.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS